Caroline Seymour joined MJH Life Sciences in 2018 and has expertise in video production and print/digital publication. Email: cseymour@onclive.com
MONALEESA-3 Data Highlight Ribociclib as Standard in HR+ Breast Cancer
September 24th 2018Findings from the MONALEESA-3 trial dispelled the theory that a CDK4/6 inhibitor had to be reserved following recurrence on hormone therapy in postmenopausal patients with hormone receptor (HR)-positive, HER2-negative breast cancer, explained Dennis J. Slamon, MD, PhD.
Multidisciplinary Approach to Adverse Event Management Imperative in GU Cancers
September 18th 2018While revisions to guidelines have given clinicians a better handle on how to manage immune-related adverse events (AEs), they have not eliminated the need for individualized treatment of patients with genitourinary (GU) cancers, says Xiao X. Wei, MD, MAS.
HR+ Breast Cancer Treatments Evolving Rapidly
August 15th 2018Over the last few years, treatments for patients with metastatic hormone receptor (HR)-positive breast cancer have evolved rapidly. As changes in care continue to progress, nurses need to understand these treatment options, and where the research may take the field in the future.
Maintenance PARP Inhibitors for Ovarian Cancer Make Meaningful Impact on PFS
May 12th 2018With the approval of rucaparib in April 2018, there are now 3 PARP inhibitors approved for use in the maintenance setting for patients with ovarian cancer who are in a complete or partial response to platinum-based chemotherapy, and they are significantly improving progression-free survival.
NCCN Guidelines on Breast Cancer Impact Clinical Applications of Radiation Therapy
April 20th 2018The National Comprehensive Cancer Network (NCCN) guidelines on breast cancer now allow physicians to pinpoint the women who are most likely to benefit from post-mastectomy radiation using the latest targeted testing techniques.